Tysabri related Press Releases
Quest Diagnostics STRATIFY JCV(TM) 1st FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in MS patients
Quest Diagnostics STRATIFY JCV(TM) First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients Based on exclusive collaboration with Biogen Idec, Read more...
FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor
WESTON, Mass. & DUBLIN--(BUSINESS WIRE)-- Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.S. Food and Drug Administration (FDA) has approved a product Read more...
Recent Multiple Sclerosis Market Events Have Resulted in Treatment Algorithm Modifications According to a Recent BioTrends
EXTON, Pa.--(BUSINESS WIRE)-- While Biogen Idec’s Avonex and Teva’s Copaxone continue to capture the majority of multiple sclerosis (MS) patients first starting on a disease-modifying agent (DMA), Read more...
While Copaxone and Interferon-Betas Continue to Dominate Treatment in MS, Tysabri Shows Modest Increase in First-Line Use
Quarterly Treatment Algorithm Analysis for Multiple Sclerosis Now Available from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and Read more...
Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations
-- Has been instrumental in reinvigorating U.S. Commercial Operations -- WESTON, Mass.--(BUSINESS WIRE)-- Biogen Idec (NASDAQ: BIIB) today announced that Tony Kingsley has been promoted to Executive Read more...
Critical Therapeutic Objectives Continue to go Unmet for the Treatment of Multiple Sclerosis Even with the Assimilation of
EXTON, Pa.--(BUSINESS WIRE)-- Trial and share of Novartis’ Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), to grow suggesting increasing acceptance Read more...
As Adoption Deepens Among Prescribers, Satisfaction with Gilenya Remains Muted Due to Continuing Issues with Novartis Supp
EXTON, Penn.--(BUSINESS WIRE)-- At six months post launch, market share of Novartis’ Gilenya, the newest disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), has increased Read more...
Neurologists Anticipate Increased Use of Novartis’ Gilenya and Biogen Idec’s Tysabri over the Next Six Months Despite Safe
EXTON, Pa.--(BUSINESS WIRE)-- Physician trial and market share of Novartis’ Gilenya, the first oral disease modifying agent (DMA) for the treatment of multiple sclerosis (MS), have both increased Read more...
While More Neurologists Are Using Gilenya Compared to Just Two Months Ago, a Number of Prescribing Obstacles Are Impeding
EXTON, Penn.--(BUSINESS WIRE)-- BioTrends Research Group, LLC finds that, while surveyed neurologists are almost unanimous in reporting that the unique mode of administration of Novartis’s Gilenya is Read more...
European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients t
EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease Read more...
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
